Is Extensive Atrial Fibrosis in the Setting of Heart Failure Associated with a Reduced Atrial Fibrillation Burden?

Overview

Journal Pacing Clin Electrophysiol

Date 2018 Aug 29

PMID 30152017

Citations 6

Authors

Alexander Burashnikov

Charles Antzelevitch

Affiliations

Soon will be listed here.

Abstract

Atrial fibrillation (AF) affects 10-50% of patients with chronic heart failure (HF) and is associated with poor long-term prognosis. AF is commonly associated with atrial structural remodeling (ASR), principally characterized by atrial dilatation and fibrosis. However, the occurrence of AF in the full spectrum of ASR encountered in patients with HF is poorly defined. Experimental studies have presented evidence that extensive ASR can be accompanied with a reduced burden of AF, secondary to a prominent depression of atrial excitability. This reduction in AF burden is associated with severe atrial fibrosis rather than with dilatation. Clinical studies of patients with HF point to the possibility that advanced ASR is associated with a less frequent AF occurrence than moderate ASR. Our goal in this review is to introduce the hypothesis that AF is less likely to occur in severe versus moderate atrial ASR in the setting of HF and that it is severe atrial fibrosis-associated depression of atrial excitability that reduces AF burden.

Citing Articles

"Pharmacological" analysis of atrial fibrillation maintenance mechanism: reentry, wavelets, or focal?.

Burashnikov A Front Cardiovasc Med. 2025; 12:1447542.

PMID: 39925977 PMC: 11802512. DOI: 10.3389/fcvm.2025.1447542.

Characterization of patients with extensive left atrial myopathy referred for atrial fibrillation ablation: incidence, predictors, and outcomes.

Gonzalez-Ferrero T, Bergonti M, Marcon L, Minguito-Carazo C, Bellas C, Pesquera Lorenzo J Clin Res Cardiol. 2024; 114(1):126-137.

PMID: 38922425 DOI: 10.1007/s00392-024-02467-6.

Advances in basic and translational research in atrial fibrillation.

Hu D, Barajas-Martinez H, Zhang Z, Duan H, Zhao Q, Bao M Philos Trans R Soc Lond B Biol Sci. 2023; 378(1879):20220174.

PMID: 37122214 PMC: 10150218. DOI: 10.1098/rstb.2022.0174.

Research Progress of Myocardial Fibrosis and Atrial Fibrillation.

Li G, Yang J, Zhang D, Wang X, Han J, Guo X Front Cardiovasc Med. 2022; 9:889706.

PMID: 35958428 PMC: 9357935. DOI: 10.3389/fcvm.2022.889706.

Atrial Fibrillation Induced by Anticancer Drugs and Underling Mechanisms.

Burashnikov A J Cardiovasc Pharmacol. 2021; 80(4):540-546.

PMID: 34803149 PMC: 10566596. DOI: 10.1097/FJC.0000000000001182.

References

Hansen B, Zhao J, Fedorov V . Fibrosis and Atrial Fibrillation: Computerized and Optical Mapping; A View into the Human Atria at Submillimeter Resolution. JACC Clin Electrophysiol. 2017; 3(6):531-546. PMC: 5693365. DOI: 10.1016/j.jacep.2017.05.002. View

Li D, Fareh S, Leung T, Nattel S . Promotion of atrial fibrillation by heart failure in dogs: atrial remodeling of a different sort. Circulation. 1999; 100(1):87-95. DOI: 10.1161/01.cir.100.1.87. View

Charitos E, Ziegler P, Stierle U, Robinson D, Graf B, Sievers H . Atrial fibrillation burden estimates derived from intermittent rhythm monitoring are unreliable estimates of the true atrial fibrillation burden. Pacing Clin Electrophysiol. 2014; 37(9):1210-8. DOI: 10.1111/pace.12389. View

Goette A, Kalman J, Aguinaga L, Akar J, Cabrera J, Chen S . EHRA/HRS/APHRS/SOLAECE expert consensus on atrial cardiomyopathies: Definition, characterization, and clinical implication. Heart Rhythm. 2016; 14(1):e3-e40. PMC: 5548137. DOI: 10.1016/j.hrthm.2016.05.028. View

Kato T, Di Tullio M, Qian M, Wu M, Thompson J, Mann D . Clinical and Echocardiographic Factors Associated With New-Onset Atrial Fibrillation in Heart Failure　- Subanalysis of the WARCEF Trial. Circ J. 2016; 80(3):619-26. DOI: 10.1253/circj.CJ-15-1054. View

Platonov P, Corino V, Seifert M, Holmqvist F, Sornmo L . Atrial fibrillatory rate in the clinical context: natural course and prediction of intervention outcome. Europace. 2014; 16 Suppl 4:iv110-iv119. DOI: 10.1093/europace/euu249. View

Uhm J, Mun H, Wi J, Shim J, Joung B, Lee M . Prolonged atrial effective refractory periods in atrial fibrillation patients associated with structural heart disease or sinus node dysfunction compared with lone atrial fibrillation. Pacing Clin Electrophysiol. 2012; 36(2):163-71. DOI: 10.1111/pace.12037. View

Swartz M, Fink G, Lutz C, Taffet S, Berenfeld O, Vikstrom K . Left versus right atrial difference in dominant frequency, K(+) channel transcripts, and fibrosis in patients developing atrial fibrillation after cardiac surgery. Heart Rhythm. 2009; 6(10):1415-22. PMC: 2790556. DOI: 10.1016/j.hrthm.2009.06.018. View

Kapoor J, Kapoor R, Ju C, Heidenreich P, Eapen Z, Hernandez A . Precipitating Clinical Factors, Heart Failure Characterization, and Outcomes in Patients Hospitalized With Heart Failure With Reduced, Borderline, and Preserved Ejection Fraction. JACC Heart Fail. 2016; 4(6):464-72. DOI: 10.1016/j.jchf.2016.02.017. View

10.

De Ferrari G, Klersy C, Ferrero P, Fantoni C, Salerno-Uriarte D, Manca L . Atrial fibrillation in heart failure patients: prevalence in daily practice and effect on the severity of symptoms. Data from the ALPHA study registry. Eur J Heart Fail. 2006; 9(5):502-9. DOI: 10.1016/j.ejheart.2006.10.021. View

11.

Martins R, Kaur K, Hwang E, Ramirez R, Willis B, Filgueiras-Rama D . Dominant frequency increase rate predicts transition from paroxysmal to long-term persistent atrial fibrillation. Circulation. 2014; 129(14):1472-82. PMC: 3981906. DOI: 10.1161/CIRCULATIONAHA.113.004742. View

12.

Haissaguerre M, Lim K, Jacquemet V, Rotter M, Dang L, Hocini M . Atrial fibrillatory cycle length: computer simulation and potential clinical importance. Europace. 2007; 9 Suppl 6:vi64-70. DOI: 10.1093/europace/eum208. View

13.

Jalife J, Kaur K . Atrial remodeling, fibrosis, and atrial fibrillation. Trends Cardiovasc Med. 2015; 25(6):475-84. PMC: 5658790. DOI: 10.1016/j.tcm.2014.12.015. View

14.

Olshansky B, Heller E, Mitchell L, Chandler M, Slater W, Green M . Are transthoracic echocardiographic parameters associated with atrial fibrillation recurrence or stroke? Results from the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) study. J Am Coll Cardiol. 2005; 45(12):2026-33. DOI: 10.1016/j.jacc.2005.03.020. View

15.

Schoonderwoerd B, van Gelder I, van Veldhuisen D, Tieleman R, Grandjean J, Bel K . Electrical remodeling and atrial dilation during atrial tachycardia are influenced by ventricular rate: role of developing tachycardiomyopathy. J Cardiovasc Electrophysiol. 2002; 12(12):1404-10. DOI: 10.1046/j.1540-8167.2001.01404.x. View

16.

Akkaya M, Higuchi K, Koopmann M, Damal K, Burgon N, Kholmovski E . Higher degree of left atrial structural remodeling in patients with atrial fibrillation and left ventricular systolic dysfunction. J Cardiovasc Electrophysiol. 2013; 24(5):485-91. DOI: 10.1111/jce.12090. View

17.

Vaziri S, Larson M, Benjamin E, Levy D . Echocardiographic predictors of nonrheumatic atrial fibrillation. The Framingham Heart Study. Circulation. 1994; 89(2):724-30. DOI: 10.1161/01.cir.89.2.724. View

18.

Gottdiener J, Kitzman D, Aurigemma G, Arnold A, Manolio T . Left atrial volume, geometry, and function in systolic and diastolic heart failure of persons > or =65 years of age (the cardiovascular health study). Am J Cardiol. 2005; 97(1):83-9. DOI: 10.1016/j.amjcard.2005.07.126. View

19.

Tardif J, OMeara E, Komajda M, Bohm M, Borer J, Ford I . Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. Eur Heart J. 2011; 32(20):2507-15. PMC: 3195263. DOI: 10.1093/eurheartj/ehr311. View

20.

Kuperstein R, Goldenberg I, Moss A, Solomon S, Bourgoun M, Shah A . Left atrial volume and the benefit of cardiac resynchronization therapy in the MADIT-CRT trial. Circ Heart Fail. 2013; 7(1):154-60. DOI: 10.1161/CIRCHEARTFAILURE.113.000748. View